Development of imatinibmesylate-induced interstitial lung disease 2 weeks after discontinuation of the treatment: a case report

BACKGROUND: Imatinibmesylate (imatinib) is a small molecule tyrosine kinase inhibitor administered to patients with chronic myelogenous leukemia and gastrointestinal stromal tumor. Although imatinib-associated interstitial lung disease is uncommon, a few cases have been reported so far. However, in...

Descrición completa

Gardado en:
Detalles Bibliográficos
Main Authors: Nakashima, Shota, Kakugawa, Tomoyuki, Motomura, Hiroko, Hirano, Katsuji, Sasaki, Eisuke, Nagata, Yasuhiro, Kinoshita, Akitoshi, Sakamoto, Noriho, Ishimatsu, Yuji, Mukae, Hiroshi, Kohno, Shigeru
Formato: Artigo
Idioma:Inglês
Publicado: BioMed Central 2012
Assuntos:
Case Report
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC3537559/
https://ncbi.nlm.nih.gov/pubmed/23174134
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/2049-6958-7-48
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares